0001209191-21-063201.txt : 20211105 0001209191-21-063201.hdr.sgml : 20211105 20211105170026 ACCESSION NUMBER: 0001209191-21-063201 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211104 FILED AS OF DATE: 20211105 DATE AS OF CHANGE: 20211105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pasternak Andy CENTRAL INDEX KEY: 0001792746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 211385383 MAIL ADDRESS: STREET 1: C/O HORIZON THERAPEUTICS PLC STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD CITY: DUBLIN STATE: L2 ZIP: D04 C5Y6 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-04 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001792746 Pasternak Andy C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHEN?S GREEN DUBLIN L2 D02 E2X4 IRELAND 0 1 0 0 EVP and Chief Business Officer Ordinary Shares 2021-11-04 4 M 0 23251 29.52 A 53523 D Ordinary Shares 2021-11-04 4 S 0 5484 110.64 D 48039 D Ordinary Shares 2021-11-04 4 S 0 6336 111.47 D 41703 D Ordinary Shares 2021-11-04 4 S 0 2706 112.44 D 38997 D Ordinary Shares 2021-11-04 4 S 0 5650 113.54 D 33347 D Ordinary Shares 2021-11-04 4 S 0 2728 114.49 D 30619 D Ordinary Shares 2021-11-04 4 S 0 7264 115.51 D 23355 D Stock Option (Right to Buy) 29.52 2021-11-04 4 M 0 23251 0.00 D 2029-10-31 Ordinary Shares 23251 23251 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.005 to $111.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.07 to $114.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.24 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested and exercisable. /s/ Miles W. McHugh, Attorney-in-Fact 2021-11-05